Please sign in to follow a disease.
Combined oxidative phosphorylation deficiency
MONDO:0000732A mitochondrial oxidative phosphorylation disorder in which multiple mitochondrial respiratory chain complexes are affected.
13 clinical trials for this condition and its sub-types, 0 tagged with Combined oxidative phosphorylation deficiency itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Combined oxidative phosphorylation deficiency
-
8 sub-types
- Combined oxidative phosphorylation deficiency 22 0 trials
- Mitochondrial complex 5 (ATP synthase) deficiency, mitochondrial type 1 0 trials
- Mitochondrial complex 5 (ATP synthase) deficiency, nuclear type 6 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4A 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4B 0 trials
- Mitochondrial complex V (ATP synthase) deficiency, nuclear type 7 0 trials
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC